View publication

↩ Back to all publications
Publication
PropertyValue
Working Groups Levin
SubprojectNone
Open AccessOpen Access Yes
Publication TypeJournal Article
Peer ReviewedYes
PMIDPubMed ID 38683602
DOIDOI 10.1001/jamaneurol.2024.0991
Publication Year2024
TitleDownstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
JournalJAMA neurology
ISSN2168-6149
ESSN2168-6157
URL https://www.ncbi.nlm.nih.gov/pubmed/?term=38683602%5Buid%5D
Pages582-593
Issue6
Volume81
Journal AbbreviationJAMA Neurol
AuthorsWagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E
First AuthorWagemann O
Last AuthorMcDade E